996热re视频精品视频这里,国产又色又爽又高潮免费,精品自拍亚洲一区在线,久久久综合九色合综,国产精品亚洲综合一区在线观看

  • Ovid, Angelini Pharma Announce Agreement for OV101 americanpharmaceuticalreview
    July 22, 2020
    Ovid Therapeutics and Angelini Pharma announced an agreement in which Angelini Pharma will be responsible to develop, manufacture and commercialize OV101 (gaboxadol) for the potential treatment of Angelman syndrome in the European Union, other countries..
  • Ovid, Angelini Pharma Enter Exclusive License Agreement contractpharma
    July 14, 2020
    To develop, manufacture and commercialize OV101 for the treatment of Angelman Syndrome in Europe.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service